Symbols

NVIV(Delisted)

Invivo Therapeutics·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NVIV

Invivo Therapeutics Holdings Corp.

A research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries

Industry

Established Date

04/02/2003

Listing Date

04/17/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.invivotherapeutics.com

Security Type

Common stock

Office address

One Kendall Square , Suite B14402 , Cambridge , Massachusetts 02139

Business

Introduction

InVivo Therapeutics Holdings Corp., incorporated under the laws of the State of Nevada on April 2, 2003, was originally named Design Source Corporation. On October 26, 2010, the Company acquired INVIVO Therapeutics, a company established in 2005, and continued the existing business operations of INVIVO Therapeutics. The company changed its name to INVIVO Therapeutics Holdings in connection with the transaction. INVIVO Therapeutics Holdings LLC is a research and clinical stage biomaterials and biotechnology company focused on the treatment of spinal cord injury. The Company's patented technology incorporates intellectual property rights from exclusive, worldwide licenses and technologies from Boston Children's Hospital (" BCH "), Massachusetts Institute of Technology (" MIT "), and intellectual property rights have been developed internally, including collaborations with the Company's advisors and partners. The company intends to use its platform technology to develop a new type of neurospinal scaffold, which is designed for spinal cord contusion implanted in the injury site and for the treatment of acute spinal cord injury, spinal cord injury or a research bioabsorbable polymer scaffold.

Company Financials

EPS

NVIV has released its 2023 Q3 earnings. EPS was reported at -0.87, versus the expected 0, missing expectations. The chart below visualizes how NVIV has performed over recent quarters, highlighting trends in earnings surprises.